Table 2. Chronic GVHD Characteristics.

	N (% or range)
All	258
Median months from transplant to cGVHD Dx	7 (2-267a)
Median months from cGVHD Dx to consent	23 (0-222)
Median months from transplant to consent	36 (4-297)
cGVHD Organ Involvementb
Skin	204 (79)
Joints and Fascia	164 (64)
Eyes	206 (80)
Mouth	176 (68)
Lungs	198 (77)
Liver	132 (51)
GI	113 (44)
Genital (females only, N=113)	64 (57)
Average NIH Organ Score	1.13 (0.14-2.14)
Number of organs affected by cGVHD	Median 5 (1-8)
1-2	12 (4)
3-4	92 (36)
5-6	111 (43)
7-8	43 (17)
NIH Global Scorec
Mild	3 (1)
Moderate	71 (28)
Severe	184 (71)
Prior cGVHD Systemic Treatment Regimens
<2	26 (10)
2-3	95 (37)
4-5	89 (34)
>5	46 (18)
Unknown	2 (1)
Intensity of Current Immunosuppressiond
None/Mild	60 (23)
Moderate	97 (38)
High	100 (39)
Unknown	1 (<1)
Current Use of Calcineurin Inhibitor
Yes	120 (47)
No	138 (53)
Prednisone-Equivalent Corticosteroid Dose
None	114 (44)
<0.25mg/kg/day	69 (26)
0.25mg/kg/day to 0.5mg/kg/day	35 (14)
>0.5mg/kg/day	40 (16)

^acGVHD diagnosed in patient after donor lymphocyte infusion; longest period from transplant to cGVHD diagnosis without intermediate donor lymphocyte infusion was 103 months

^bcGVHD organ involvement per NIH organ staging (28).

^cDefinition for NIH Global score is as follows: mild (1 to 2 organs affected by chronic GVHD with scores of 1), moderate (more than 2 organs with score of 1, any score of 2, or lung score of 1), or severe (any score of 3 or lung score of 2) (28).

^dDefinition of intensity of current immunosuppression is as follows: mild (single-agent prednisone 0.5mg/kg/day), moderate (single-agent prednisone 0.5mg/kg/day and/or any single agent/modality), high (2 or more agents/modalities +/- prednisone 0.5mg/kg/day) (4).

Abbreviations: cGVHD–Chronic GVHD, Dx–Diagnosis, GI–Gastrointestinal